For Research Use Only — Not for Human or Veterinary Use
CJC / Ipamorelin Refill 10mg is supplied exclusively for in vitro and pre-clinical in vivo research use with the AbsoluteBioLab Reusable Metal Peptide Pen v3. This product has not been evaluated by the MHRA, FDA, or any other regulatory authority for safety or efficacy in humans or animals. Purchase confirms the buyer is a qualified researcher.
CJC / Ipamorelin Refill 10mg — Dual GH Secretagogue Blend Refill Cartridge for the AbsoluteBioLab Peptide Pen v3
The CJC / Ipamorelin Refill 10mg is a pre-filled lyophilised refill cartridge containing a research-grade blend of CJC-1295 (without DAC) and Ipamorelin — two complementary growth hormone secretagogues that act through distinct but synergistic receptor mechanisms to stimulate pulsatile growth hormone (GH) release. This refill format is designed for direct use with the AbsoluteBioLab Reusable Metal Peptide Pen v3, providing a convenient and reproducible format for pre-clinical GH axis research programmes.
Each refill cartridge contains a total of 10mg of the lyophilised blend (CJC-1295 and Ipamorelin in a defined ratio), verified by RP-HPLC to a minimum purity of ≥99.0% for each component, with molecular identities confirmed by ESI-MS. Endotoxin content is certified at <1.0 EU/mg by kinetic turbidimetric LAL assay. A batch-specific Certificate of Analysis is included with every order.
CJC-1295 (without DAC) is a 30-amino-acid synthetic analogue of growth hormone-releasing hormone (GHRH) that acts as a GHRH receptor (GHRHR) agonist. Unlike CJC-1295 with DAC (drug affinity complex), the without-DAC form has a shorter half-life (~30 minutes) and produces a more physiological, pulsatile pattern of GH release that more closely mirrors endogenous GHRH signalling. CJC-1295 activates GHRHR on somatotroph cells in the anterior pituitary, stimulating adenylyl cyclase activity, cAMP production, and downstream PKA/CREB signalling that drives GH synthesis and release.
Ipamorelin is a selective growth hormone secretagogue receptor (GHSR-1a) agonist — a pentapeptide (Aib-His-D-2-Nal-D-Phe-Lys-NH₂) that mimics the action of ghrelin at GHSR-1a without the off-target effects on cortisol, prolactin, or ACTH that are associated with earlier GHSRPs such as GHRP-2 and GHRP-6. The combination of CJC-1295 (GHRHR agonist) and Ipamorelin (GHSR-1a agonist) provides dual-pathway stimulation of GH release, with the two compounds acting synergistically to produce a greater GH pulse than either compound alone.
Compound Identity & Molecular Data
| Parameter | Value |
|---|---|
| Compound 1 | CJC-1295 (without DAC) — GHRH(1-29) analogue |
| CJC-1295 MW | 3,367.97 Da (free base, monoisotopic) |
| CJC-1295 CAS | 863288-34-0 |
| Compound 2 | Ipamorelin — GHSR-1a selective agonist pentapeptide |
| Ipamorelin MW | 711.87 Da (free base, monoisotopic) |
| Ipamorelin CAS | 170851-70-4 |
| Total Quantity per Cartridge | 10 mg (blend; defined CJC-1295 : Ipamorelin ratio) |
| Primary Receptors | GHRHR (CJC-1295); GHSR-1a (Ipamorelin) |
| Research Classification | Dual GH secretagogue blend; pulsatile GH release; GH axis research |
Analytical Release Testing — Refill Cartridge Specification
| Test | Method | Specification | Notes |
|---|---|---|---|
| Purity (each component) | RP-HPLC (C18, UV 220 nm) | ≥99.0% | Acetonitrile/water gradient; TFA modifier |
| Identity (each component) | ESI-MS | Confirmed ±0.1 Da | Electrospray ionisation mass spectrometry |
| Endotoxin | Kinetic turbidimetric LAL | <1.0 EU/mg | USP <85> compliant method |
| Residual Moisture | Karl Fischer titration | <5.0% | Coulometric KF; lyophilisation quality indicator |
| Total Quantity per Cartridge | Gravimetric | 10 mg ± 5% | Lyophilised acetate salt blend; net peptide content |
| Compatible Device | — | AbsoluteBioLab Peptide Pen v3 | Use with 4mm 31G pen needles |
Mechanism of Action
CJC-1295 (without DAC) activates the GHRH receptor (GHRHR) on anterior pituitary somatotroph cells, stimulating adenylyl cyclase, cAMP production, and PKA/CREB-mediated transcription of GH. GHRHR activation also mobilises intracellular calcium through IP₃-mediated pathways, contributing to GH secretory granule exocytosis. The without-DAC form of CJC-1295 lacks the maleimido-propionic acid modification that enables covalent binding to serum albumin in the DAC version, resulting in a shorter plasma half-life (~30 minutes) that produces a more physiological, pulsatile GH release pattern compared to the prolonged, non-pulsatile GH elevation produced by CJC-1295 with DAC.
Ipamorelin activates GHSR-1a (ghrelin receptor) on somatotrophs through a distinct Gq/11-coupled pathway, mobilising intracellular calcium and activating PKC, which synergises with the cAMP/PKA pathway activated by CJC-1295 to produce a supra-additive GH pulse. The selectivity of Ipamorelin for GHSR-1a — without significant activity at ACTH, cortisol, or prolactin pathways — makes it a preferred research tool for clean GH axis stimulation studies compared to earlier GHSRPs such as GHRP-2 and GHRP-6, which activate multiple pituitary axes and confound interpretation of GH-specific effects.
The pharmacodynamic synergy between CJC-1295 and Ipamorelin has been demonstrated in multiple pre-clinical studies showing that co-administration produces a significantly greater GH pulse amplitude than either compound alone, without a corresponding increase in IGF-1 suppression or somatostatin feedback. This synergistic GH release profile makes the CJC/Ipamorelin blend a widely used research tool for investigating GH axis regulation, somatotroph biology, and the downstream effects of pulsatile GH on IGF-1 production, body composition, and metabolic function in pre-clinical models.
Research Applications
The CJC / Ipamorelin Refill is used in pre-clinical GH axis research programmes investigating the mechanisms of pulsatile GH release, somatotroph biology, and the metabolic effects of GH/IGF-1 axis stimulation. Research applications include studies of GH deficiency models, body composition changes in response to GH axis stimulation, the effects of pulsatile vs. continuous GH on IGF-1 production, and the downstream effects of GH/IGF-1 on muscle, bone, and adipose tissue in rodent models. The dual-compound blend format is particularly suited to research programmes that have established protocols using the combined CJC/Ipamorelin approach and wish to maintain consistency across experimental cohorts.
Reconstitution & Handling Guidance
CJC / Ipamorelin Refill cartridges are supplied in lyophilised form and must be reconstituted before use. For use with the AbsoluteBioLab Peptide Pen v3, reconstitute the cartridge with bacteriostatic water to the desired concentration. A typical reconstitution is 2ml bacteriostatic water per 10mg cartridge to yield a 5mg/ml total peptide solution. Allow the lyophilised cake to dissolve completely by gentle swirling — do not vortex. The reconstituted solution should be clear and colourless; discard if particulate matter or discolouration is observed.
Storage & Stability
| Condition | Temperature | Duration | Notes |
|---|---|---|---|
| Lyophilised cartridge (long-term) | −20°C | ≥24 months | Desiccated; protect from light and moisture |
| Lyophilised cartridge (short-term) | 2–8°C | Up to 4 weeks | Desiccated; suitable for active research use |
| Reconstituted in bacteriostatic water | 2–8°C | Up to 28 days | Benzyl alcohol preservative extends stability |
| Reconstituted aliquots (extended) | −80°C | Up to 12 months | Single-use aliquots; avoid repeated freeze-thaw cycles |
Reviews
There are no reviews yet.